Showing 841 - 860 results of 99,977 for search '(( 5 ((nm decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (nn decrease)) ))', query time: 1.37s Refine Results
  1. 841
  2. 842
  3. 843
  4. 844
  5. 845

    Top 5 templates of CNN1 isoform 2 by PHYRE2 tool. by Muhammad Bilal Azmi (14519913)

    Published 2023
    “…<div><p>Prematurity is the foremost cause of death in children under 5 years of age. Genetics contributes to 25–40% of all preterm births (PTB) yet we still need to identify specific targets for intervention based on genetic pathways. …”
  6. 846
  7. 847
  8. 848

    R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

    Published 2022
    “…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”
  9. 849

    R346K Mutation in the <i>Mu</i> Variant of SARS-CoV‑2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study by Filip Fratev (1799740)

    Published 2022
    “…The <i>Mu</i> variant of SARS-CoV-2 has been recently classified as a variant of interest (VOI) by the World Health Organization (WHO) but limited data are available at the moment. …”
  10. 850
  11. 851
  12. 852
  13. 853
  14. 854
  15. 855

    A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity by Regina Michelis (2889092)

    Published 2019
    “…In patients with abnormal C5, basal levels of sC5b-9 and C5a were increased while activities of the CP and of the CP C5-convertase, the immediate C5-upstream complex, were decreased compared to NC and to patients with normal C5. …”
  16. 856
  17. 857
  18. 858
  19. 859
  20. 860

    Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera by Angela Bozza (8908091)

    Published 2023
    “…After the discovery of a mutation in the Janus kinase 2 (<i>JAK</i>2<sup>V617F</sup>), JAK2 inhibitors have been tested as second-line therapies. …”